Co-Diagnostics, Inc. (NASDAQ:CODX) Sees Significant Decrease in Short Interest

Co-Diagnostics, Inc. (NASDAQ:CODX) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 208,700 shares, a drop of 7.8% from the October 15th total of 226,400 shares. Based on an average daily volume of 246,900 shares, the short-interest ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 price objective on shares of Co-Diagnostics in a research note on Monday, November 11th.

Co-Diagnostics Stock Down 0.9 %

CODX opened at $1.07 on Wednesday. Co-Diagnostics has a 52 week low of $1.00 and a 52 week high of $2.23. The firm has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $1.25. The company has a market capitalization of $34.17 million, a PE ratio of -0.78 and a beta of -0.84.

Hedge Funds Weigh In On Co-Diagnostics

A hedge fund recently bought a new stake in Co-Diagnostics stock. Jane Street Group LLC bought a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned about 0.14% of Co-Diagnostics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.